COMP <GO>
GRC vs TMO // EV/EBITDA & P/E VALUATION
Gorman-Rupp Company (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: GRC 5
— TMO 5
▲ EV/EBITDA & P/E VALUATION LEADER: GRC
LAST: $74.39 (-0.61%) • MKT CAP: $1.96B
valuation
23.2x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRC VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRC | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.30% | 9.30% | +2.00 | GRC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 23.2x | 30.4x | -7.20 | GRC | /valuation <GO> |
| Free Cash Flow Yield | 5.41% | 2.40% | +3.01 | GRC | /fcf-yield <GO> |
| Operating Margin | 14.00% | 17.40% | -3.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.80% | 15.10% | -7.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | — | 3.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.68 | 4.50 | +0.18 | GRC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.3 | 62.9 | -19.57 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 36.3x | -1.80 | GRC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.96B | $262.22B | -$260.25B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRC REV | TMO REV | GRC GROSS % | TMO GROSS % | GRC FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $682.4M | $44.56B | 30.6% | — | $106.2M | $6.29B |
| FY 2024 | $659.7M | $42.88B | 31.0% | — | $69.8M | $7.27B |
| FY 2023 | $0 | $42.86B | — | — | $98.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRC // BETA —
TMO // BETA 0.94